Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis
ICD-10 N01.5 is a billable code used to indicate a diagnosis of rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis.
Rapidly progressive nephritic syndrome (RPNS) is characterized by a swift decline in renal function, often leading to end-stage renal disease within weeks to months. This syndrome is associated with diffuse mesangiocapillary glomerulonephritis, which involves the proliferation of mesangial cells and thickening of the capillary walls, resulting in significant proteinuria and hematuria. Clinically, patients may present with symptoms such as edema, hypertension, and oliguria. Laboratory findings typically reveal elevated serum creatinine levels, significant proteinuria, and hematuria. A renal biopsy is crucial for diagnosis, showing mesangial proliferation and capillary wall changes. Management involves addressing the underlying cause, which may include immunosuppressive therapy, and supportive care such as blood pressure control and diuretics. Early intervention is critical to prevent irreversible kidney damage.
Comprehensive documentation of clinical findings, lab results, and treatment plans.
Patients presenting with acute renal failure, significant proteinuria, and hematuria.
Ensure renal biopsy findings are clearly documented to support the diagnosis.
Detailed pathology reports describing histological findings.
Biopsy evaluations for suspected glomerulonephritis.
Pathology reports should include specific findings related to mesangiocapillary changes.
Used when a renal biopsy is performed to confirm diagnosis.
Biopsy report must be included in the patient's medical record.
Nephrologists should ensure that the biopsy findings correlate with clinical symptoms.
The primary treatment involves addressing the underlying cause, which may include immunosuppressive therapy, along with supportive care for renal function.
